Tag: executive

FORT WAYNE, Ind., July 07, 2025 (GLOBE NEWSWIRE) -- Franklin Electric Co., Inc. (NASDAQ: FELE) announced that Daniela Williams will join its executive leadership team as Chief Human Resources Officer (CHRO), bringing a proven track record of driving growth for global organizations.

ST. JOHN'S, Newfoundland and Labrador, July 07, 2025 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its second quarter 2025 financial results on Friday, August 1, 2025. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's second quarter financial results.

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET.

Ridgway, Colorado , July 07, 2025 (GLOBE NEWSWIRE) -- This is True, a weekly online publication focused on unusual news stories and social commentary, announced today that founder Randy Cassingham and executive coach Kit Cassingham have relocated to full-time residency aboard a residential cruise ship. The couple has moved their professional operations to the Villa Vie Odyssey, a ship adapted for permanent living and remote work, reflecting evolving lifestyle trends among digital professionals.

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

VERO BEACH, Fla., July 07, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the second quarter of 2025 following the close of trading on the New York Stock Exchange on Thursday, July 24, 2025.